ArticleJournal of cardiothoracic surgery2025
Outcomes of conservative management for chylothorax following minimally invasive lung cancer surgery.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Incidence and management outcomes of chylothorax after pulmonary resection for primary lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Re-evaluating the anatomy of iatrogenic chylothorax - lymphangiography imaging of the transverse branch of the thoracic duct.Updates in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMinimally invasive surgery (MIS) has become a mainstay for lung cancer treatment because of comparable outcomes to open thoracotomy; however, chylothorax remains a notable complication, which can lead to protein and electrolyte depletion, malnutrition, and increased morbidity. This study aimed to (1) determine the incidence of chylothorax after MIS for lung cancer; (2) identify pertinent risk factors; (3) evaluate the effectiveness and limitations of a predominantly conservative treatment algorithm; and (4) assess perioperative changes in nutritional status associated with chyle leakage.
methodsThis single-center, retrospective cohort study included patients who underwent multiport or single-port video-assisted thoracoscopic surgery, or robot-assisted thoracoscopic surgery at our institution between September 2009 and August 2024. Chylothorax was diagnosed based on visual and laboratory confirmation (pleural fluid triglyceride ≥ 110 mg/dL or high lymphocyte fraction), and was managed using a stepwise protocol including total parenteral nutrition (TPN), no-fat or low-fat diet, and pleurodesis as needed. If high output persisted or recurred, reoperation or thoracic duct ligation was considered. Patients were categorized into high-volume (HV) or low-volume chylothorax groups, using a threshold of 500 mL/day to reflect severity. The outcomes included chest tube duration, hospital stay, perioperative nutritional parameters (albumin, white blood cell count, and total lymphocyte count), and nutritional risk scores.
resultsAmong the 1,038 patients included, 21 (2.0%) developed chylothorax. Risk factors for chylous leakage included right-sided tumors (p = 0.04), single-port or robotic approaches (p = 0.017), and a higher median number of dissected lymph nodes (p = 0.005) and N2 nodes (p = 0.001). Patients with chylothorax had a significantly longer chest tube duration (p < 0.001) and postoperative hospital stay (p < 0.001). Although conservative management was successful in most cases, the HV group had greater drainage volumes, more frequent pleurodesis, extended dietary interventions, and delayed recovery. Notable declines in albumin and total lymphocyte counts, and increased nutritional risk scores, underscored the metabolic burden posed by chylothorax.
conclusionChylothorax remains an important complication of MIS for lung cancer. Conservative measures are effective for many patients; however high-output chylothorax can prolong hospital stay and compromise nutritional status. Early recognition of the risk factors and judicious consideration of interventional and surgical options are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.